Els Deklerck1, Hannelore Denys2, Elke O Kreps3. 1. Department of Ophthalmology, Ghent University Hospital, 10, Corneel Heymanslaan, 9000, Ghent, Belgium. Els.Deklerck@UGent.be. 2. Department of Medical Oncology, Ghent University Hospital, 10, Corneel Heymanslaan, 9000, Ghent, Belgium. 3. Department of Ophthalmology, Ghent University Hospital, 10, Corneel Heymanslaan, 9000, Ghent, Belgium.
Abstract
PURPOSE: Ado-trastuzumab emtansine (T-DM1/Kadcyla®;Genentech) is an antibody-drug conjugate used in the treatment of human epidermal growth factor receptor-2-positive metastasized breast cancer. Few studies report a spectrum of corneal changes in patients treated with this drug. Our aim is to specify the nature and prevalence of corneal features of T-DM1 treatment in order to formulate guidelines as to which findings necessitate systemic treatment cessation or dose reduction. METHODS: We performed a cross-sectional, prospective study in all patients currently treated with T-DM1 or recently stopped in Ghent University Hospital, Belgium. RESULTS: A total of 12 patients completed a full ophthalmic workup. Ten patients were currently using T-DM1, and two patients had recently (< 10 weeks) stopped treatment because of clinical non-response. Twenty eyes of 10 patients currently on T-DM1-treatment all exhibited coarse cystoid lesions to the deep corneal epithelial cells, primarily in the midperipheral area, both biomicroscopically and on confocal microscopy. The two patients who stopped treatment, displayed no corneal epithelial changes. Only three patients reported symptoms which were attributed to other ocular factors, likely not to be related to T-DM1 treatment. CONCLUSIONS: This case series shows that asymptomatic, low-grade corneal epithelial changes are hallmark features in T-DM1-treatment and should not alarm clinicians. These findings are relatively stationary, reversible and thus do not require ocular treatment or cessation of systemic treatment.
PURPOSE:Ado-trastuzumabemtansine (T-DM1/Kadcyla®;Genentech) is an antibody-drug conjugate used in the treatment of humanepidermal growth factor receptor-2-positive metastasized breast cancer. Few studies report a spectrum of corneal changes in patients treated with this drug. Our aim is to specify the nature and prevalence of corneal features of T-DM1 treatment in order to formulate guidelines as to which findings necessitate systemic treatment cessation or dose reduction. METHODS: We performed a cross-sectional, prospective study in all patients currently treated with T-DM1 or recently stopped in Ghent University Hospital, Belgium. RESULTS: A total of 12 patients completed a full ophthalmic workup. Ten patients were currently using T-DM1, and two patients had recently (< 10 weeks) stopped treatment because of clinical non-response. Twenty eyes of 10 patients currently on T-DM1-treatment all exhibited coarse cystoid lesions to the deep corneal epithelial cells, primarily in the midperipheral area, both biomicroscopically and on confocal microscopy. The two patients who stopped treatment, displayed no corneal epithelial changes. Only three patients reported symptoms which were attributed to other ocular factors, likely not to be related to T-DM1 treatment. CONCLUSIONS: This case series shows that asymptomatic, low-grade corneal epithelial changes are hallmark features in T-DM1-treatment and should not alarm clinicians. These findings are relatively stationary, reversible and thus do not require ocular treatment or cessation of systemic treatment.
Entities:
Keywords:
Ado-trastuzumab emtansine; Breast cancer; Corneal toxicity; HER2; T-DM1
Authors: Julia Canestraro; Malin Hultcrantz; Shanu Modi; Paul A Hamlin; Alexander N Shoushtari; Jason A Konner; William P Tew; Neil M Iyengar; Murk Heinemann; David H Abramson; Jasmine H Francis Journal: Cornea Date: 2021-11-23 Impact factor: 3.152
Authors: Asim V Farooq; Simona Degli Esposti; Rakesh Popat; Praneetha Thulasi; Sagar Lonial; Ajay K Nooka; Andrzej Jakubowiak; Douglas Sborov; Brian E Zaugg; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Joanna Opalinska; January Baron; Trisha Piontek; Julie Byrne; Ira Gupta; Kathryn Colby Journal: Ophthalmol Ther Date: 2020-07-25
Authors: Katharina A Sterenczak; Nadine Stache; Sebastian Bohn; Stephan Allgeier; Bernd Köhler; Andreas Bartschat; Christian George; Rudolf F Guthoff; Oliver Stachs; Angrit Stachs Journal: Diagnostics (Basel) Date: 2021-05-07
Authors: Nancy Louisa Merridew; Ravinder Singh Phagura; Edward Anderson; Louise Anne Cooley; Graeme Alfred Pollock; Belinda McEwan; Paul James McCartney; Mohamad-Ali Trad Journal: Open Forum Infect Dis Date: 2019-07-22 Impact factor: 3.835